Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 14, 2014; 20(42): 15499-15517
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15499
Table 1 Vasodilating and vasoconstricting forces involved in disturbed haemodynamics in cirrhosis (Alphabetic order)
Vasodilator systems
Adenosine
Adrenomedullin
Atrial natriuretic peptide
Bradykinin
Brain natriuretic peptide
Calcitonin gene-related peptide
Carbon monoxide
Endocannabinoids
Endothelin-3
Endotoxin
Enkephalins
Glucagon
Histamine
Hydrogen sulphide
Interleukins
Natriuretic peptide of type C
Nitric oxide
Prostacyclin (PGI2)
Substance P
Tumour necrosis factor-α
Vasoactive intestinal polypeptide
Vasoconstrictor systems
Angiotensin II
Adrenaline and noradrenaline
Endothelin-1
Neuropeptide Y
Renin-angiotensin-aldosterone system
Sympathetic nervous system
Vasopressin
Table 2 Circulatory changes in specific vascular beds in cirrhosis
Systemic circulation
Plasma volume ↑
Total blood volume ↑
Non-central blood volume ↑
Central and arterial blood volume ↓ (→)
Cardiac output ↑
Arterial blood pressure ↓ (→)
Heart rate ↑
Systemic vascular resistance ↓
Arterial and total vascular compliance ↑
Heart
Left atrial volume ↑
Left ventricular volume → (↑)
Right atrial volume →↑↓
Right ventricular volume →↑↓
Right atrial pressure →↑
Right ventricular end diastolic pressure →
Pulmonary artery pressure →↑
Left ventricular end diastolic pressure →
Hepatic and splanchnic circulation
Hepatic blood flow ↓→ (↑)
Hepatic venous pressure gradient ↑
Postsinusoidal resistance ↑
Renal circulation
Renal blood flow ↓
Glomerular filtration rate ↓→
Pulmonary circulation
Pulmonary blood flow ↑
Pulmonary vascular resistance ↓ (↑)1
Cutaneous and skeletal muscle circulation
Skeletal muscular blood flow ↑→↓
Cutaneous blood flow ↑→↓
Table 3 Characterization of cirrhotic cardiomyopathy
Definition
A cardiac dysfunction in patients with cirrhosis characterised by impaired contractile responsiveness to stress and/or altered diastolic relaxation with electrophysiological abnormalities in the absence of other known cardiac disease
Diagnostic criteria
Systolic dysfunction
Blunted increase in cardiac output with exercise, volume challenge or pharmacological stimuli
Resting EF < 55%
Diastolic dysfunction
E/A ratio < 1.0 (age-corrected)
Prolonged deceleration time (> 200 ms)
Prolonged isovolumetric relaxation time (> 80 ms)
Supportive criteria
Electrophysiological abnormalities
Abnormal chronotropic response
Electromechanical uncoupling/dyssynchrony
Prolonged Q-T interval
Enlarged left atrium
Increased myocardial mass
Increased BNP and pro-BNP
Increased troponin I
Table 4 Diagnostic criteria for the hepatopulmonary syndrome and portopulmonary hypertension
HPSPoPH
Presence of liver diseasePresence of liver disease and portal hypertension
PA-aO2 > 15 mmHg (> 2 kPa)Mean pulmonary arterial pressure > 25 mmHg
Positive contrast enhanced echocardiography1Pulmonary vascular resistance > 240 dyn·s·cm-5 left atrial pressure < 15 mmHg
Table 5 New diagnostic criteria for the hepatorenal syndrome from the International Ascites Club (2013)[192]
Cirrhosis with ascites
Serum creatinine > 133 μmol/L (1.5 mg/dL)
No improvement of serum creatinine (decrease to a level of < 133 μmol/L) after at least 2 d with diuretic withdrawal and volume expansion with albumin. 1 g/kg of body weight per day up to a maximum of 100 g/d
Absence of shock
No current treatment with nephrotoxic drugs
Absence of parenchymal kidney disease as indicated by proteinuria > 500 mg/d, or microhaematuria, (> 50 red blood cells per high power field) and /or a normal renal ultrasonography